Scholarlink

<p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and exhibits significant molecular heterogeneity, leading to varied treatment responses among patients. Although Chimeric Antigen Receptor T-cell therapy (CAR-T) has made remarkable progress in relapsed/refractory (R/R) DLBCL, particularly in patients resistant to standard treatments, the therapeutic efficacy of CAR-T therapy remains inconsistent for high-risk subtypes, such as double-hit/triple-hit lymphoma (DHL/THL) and <i>TP53</i> mutations. This paper focuses on the molecular subtyping of DLBCL and its application in CAR-T therapy. By analyzing factors such as metabolic stress, immune evasion, and epigenetic regulation, this study reveals how these mechanisms influence the function and efficacy of CAR-T cells. Furthermore, it discusses strategies for overcoming treatment challenges in high-risk subtypes through molecular profiling, metabolic modulation, epigenetic interventions, and multi-target combination therapies. The paper also explores future research directions in CAR-T cell engineering and immune evasion mechanisms. This research provides a novel theoretical framework for personalized treatment and offers valuable insights for clinical treatment strategies for high-risk DLBCL patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Rubing Zheng,
  • Xiaojian Zhu,
  • Yi Xiao

摘要

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and exhibits significant molecular heterogeneity, leading to varied treatment responses among patients. Although Chimeric Antigen Receptor T-cell therapy (CAR-T) has made remarkable progress in relapsed/refractory (R/R) DLBCL, particularly in patients resistant to standard treatments, the therapeutic efficacy of CAR-T therapy remains inconsistent for high-risk subtypes, such as double-hit/triple-hit lymphoma (DHL/THL) and TP53 mutations. This paper focuses on the molecular subtyping of DLBCL and its application in CAR-T therapy. By analyzing factors such as metabolic stress, immune evasion, and epigenetic regulation, this study reveals how these mechanisms influence the function and efficacy of CAR-T cells. Furthermore, it discusses strategies for overcoming treatment challenges in high-risk subtypes through molecular profiling, metabolic modulation, epigenetic interventions, and multi-target combination therapies. The paper also explores future research directions in CAR-T cell engineering and immune evasion mechanisms. This research provides a novel theoretical framework for personalized treatment and offers valuable insights for clinical treatment strategies for high-risk DLBCL patients.